JP2006507270A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006507270A5 JP2006507270A5 JP2004545186A JP2004545186A JP2006507270A5 JP 2006507270 A5 JP2006507270 A5 JP 2006507270A5 JP 2004545186 A JP2004545186 A JP 2004545186A JP 2004545186 A JP2004545186 A JP 2004545186A JP 2006507270 A5 JP2006507270 A5 JP 2006507270A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- beta
- gastrointestinal
- infection
- microbial infection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 11
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 9
- 208000015181 infectious disease Diseases 0.000 claims 9
- 230000000813 microbial effect Effects 0.000 claims 8
- 208000010643 digestive system disease Diseases 0.000 claims 7
- 208000018685 gastrointestinal system disease Diseases 0.000 claims 7
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 229920001184 polypeptide Polymers 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 208000035874 Excoriation Diseases 0.000 claims 1
- 206010017964 Gastrointestinal infection Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 102000001708 Protein Isoforms Human genes 0.000 claims 1
- 108010029485 Protein Isoforms Proteins 0.000 claims 1
- 102000007501 Thymosin Human genes 0.000 claims 1
- 108010046075 Thymosin Proteins 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 230000005856 abnormality Effects 0.000 claims 1
- 238000005299 abrasion Methods 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 208000022338 anthrax infection Diseases 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 208000019836 digestive system infectious disease Diseases 0.000 claims 1
- 230000002068 genetic effect Effects 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 208000003265 stomatitis Diseases 0.000 claims 1
- 150000003462 sulfoxides Chemical class 0.000 claims 1
- LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35425002P | 2002-02-06 | 2002-02-06 | |
| US42103802P | 2002-10-25 | 2002-10-25 | |
| PCT/US2003/003455 WO2004035008A2 (en) | 2002-02-06 | 2003-02-06 | Treatment of infections and other disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006507270A JP2006507270A (ja) | 2006-03-02 |
| JP2006507270A5 true JP2006507270A5 (enExample) | 2006-04-13 |
Family
ID=32109894
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004545186A Pending JP2006507270A (ja) | 2002-02-06 | 2003-02-06 | 感染症および他の疾患の治療 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20060089310A1 (enExample) |
| EP (2) | EP2266595A3 (enExample) |
| JP (1) | JP2006507270A (enExample) |
| AU (1) | AU2003296875B2 (enExample) |
| CA (1) | CA2475053A1 (enExample) |
| WO (1) | WO2004035008A2 (enExample) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006076254A2 (en) * | 2005-01-11 | 2006-07-20 | Regenerx Biopharmaceuticals, Inc. | Method of treating or preventing respiratory microbial infection of respiratory tissue |
| US9408891B2 (en) | 2003-11-12 | 2016-08-09 | The Trustees Of The University Of Pennsylvania | Methods of using gelsolin to treat or prevent bacterial sepsis |
| AU2011218617B2 (en) * | 2004-05-12 | 2014-09-04 | The Brigham And Women's Hospital, Inc. | Use of gelsolin to treat infections |
| CA2607686C (en) | 2004-05-12 | 2014-11-04 | Thomas P. Stossel | Use of gelsolin to treat infections |
| KR100716119B1 (ko) * | 2005-10-24 | 2007-05-10 | (주)케어젠 | 모발 성장을 촉진하는 펩티드 및 이를 이용한 화장품 |
| AU2007227613A1 (en) | 2006-03-15 | 2007-09-27 | The Brigham And Women's Hospital, Inc. | Use of gelsolin to diagnose and treat inflammatory diseases |
| EP2002258B1 (en) | 2006-03-15 | 2017-09-27 | The Brigham and Women's Hospital, Inc. | Use of gelsolin to treat multiple sclerosis and to diagnose neurologic diseases |
| US8399412B2 (en) | 2006-10-06 | 2013-03-19 | Regenerx Biopharmaceuticals, Inc. | Method of treating or preventing tissue deterioration, injury or damage due to periodontal disease or disease of oral mucosa, and/or downregulating NF-kappabeta or supressing NF-kappabeta-mediated actions |
| KR20100057050A (ko) * | 2007-09-11 | 2010-05-28 | 몬도바이오테크 래보래토리즈 아게 | 치료제로서의 데슬로렐린 및 마스토파란의 용도 |
| US20100210540A1 (en) * | 2007-09-11 | 2010-08-19 | Dorian Bevec | Use of the peptide combination thymosin beta 4 and delta sleep inducing peptide as a therapeutic agent |
| JP5778425B2 (ja) | 2008-01-25 | 2015-09-16 | ザ ジェネラル ホスピタル コーポレイション | 腎不全におけるゲルソリンの診断的および治療的使用 |
| MX2010010177A (es) * | 2008-03-17 | 2012-08-23 | Regenerx Biopharmaceuticals | Fragmentos de beta timosina mejorada. |
| US8609604B2 (en) | 2009-12-28 | 2013-12-17 | N.V. Perricone Llc | Methods of improving the appearance of aging skin |
| US8580742B2 (en) | 2010-03-05 | 2013-11-12 | N.V. Perricone Llc | Topical glutathione formulations for menopausal skin |
| US20110160144A1 (en) * | 2009-12-28 | 2011-06-30 | Perricone Nicholas V | Topical Acyl Glutathione Formulations |
| BR112013000923A2 (pt) * | 2010-07-14 | 2016-05-17 | Adistem Ltd | método de tratamento de hiv ou aids |
| CN103724422B (zh) * | 2014-01-13 | 2015-10-21 | 哈尔滨吉象隆生物技术有限公司 | 一种裂解胸腺素β4的方法 |
| US10409955B2 (en) | 2014-10-21 | 2019-09-10 | uBiome, Inc. | Method and system for microbiome-derived diagnostics and therapeutics for locomotor system conditions |
| EP3209803A4 (en) | 2014-10-21 | 2018-06-13 | Ubiome, Inc. | Method and system for microbiome-derived diagnostics and therapeutics |
| US10793907B2 (en) | 2014-10-21 | 2020-10-06 | Psomagen, Inc. | Method and system for microbiome-derived diagnostics and therapeutics for endocrine system conditions |
| US10311973B2 (en) | 2014-10-21 | 2019-06-04 | uBiome, Inc. | Method and system for microbiome-derived diagnostics and therapeutics for autoimmune system conditions |
| US10366793B2 (en) | 2014-10-21 | 2019-07-30 | uBiome, Inc. | Method and system for characterizing microorganism-related conditions |
| US11783914B2 (en) | 2014-10-21 | 2023-10-10 | Psomagen, Inc. | Method and system for panel characterizations |
| US10357157B2 (en) | 2014-10-21 | 2019-07-23 | uBiome, Inc. | Method and system for microbiome-derived characterization, diagnostics and therapeutics for conditions associated with functional features |
| US10169541B2 (en) | 2014-10-21 | 2019-01-01 | uBiome, Inc. | Method and systems for characterizing skin related conditions |
| US10381112B2 (en) | 2014-10-21 | 2019-08-13 | uBiome, Inc. | Method and system for characterizing allergy-related conditions associated with microorganisms |
| US10789334B2 (en) | 2014-10-21 | 2020-09-29 | Psomagen, Inc. | Method and system for microbial pharmacogenomics |
| US9760676B2 (en) | 2014-10-21 | 2017-09-12 | uBiome, Inc. | Method and system for microbiome-derived diagnostics and therapeutics for endocrine system conditions |
| US9754080B2 (en) | 2014-10-21 | 2017-09-05 | uBiome, Inc. | Method and system for microbiome-derived characterization, diagnostics and therapeutics for cardiovascular disease conditions |
| US10265009B2 (en) | 2014-10-21 | 2019-04-23 | uBiome, Inc. | Method and system for microbiome-derived diagnostics and therapeutics for conditions associated with microbiome taxonomic features |
| US10073952B2 (en) | 2014-10-21 | 2018-09-11 | uBiome, Inc. | Method and system for microbiome-derived diagnostics and therapeutics for autoimmune system conditions |
| US10325685B2 (en) | 2014-10-21 | 2019-06-18 | uBiome, Inc. | Method and system for characterizing diet-related conditions |
| US10410749B2 (en) | 2014-10-21 | 2019-09-10 | uBiome, Inc. | Method and system for microbiome-derived characterization, diagnostics and therapeutics for cutaneous conditions |
| US9710606B2 (en) | 2014-10-21 | 2017-07-18 | uBiome, Inc. | Method and system for microbiome-derived diagnostics and therapeutics for neurological health issues |
| US9758839B2 (en) | 2014-10-21 | 2017-09-12 | uBiome, Inc. | Method and system for microbiome-derived diagnostics and therapeutics for conditions associated with microbiome functional features |
| US10395777B2 (en) | 2014-10-21 | 2019-08-27 | uBiome, Inc. | Method and system for characterizing microorganism-associated sleep-related conditions |
| US10388407B2 (en) | 2014-10-21 | 2019-08-20 | uBiome, Inc. | Method and system for characterizing a headache-related condition |
| US10346592B2 (en) | 2014-10-21 | 2019-07-09 | uBiome, Inc. | Method and system for microbiome-derived diagnostics and therapeutics for neurological health issues |
| US10777320B2 (en) | 2014-10-21 | 2020-09-15 | Psomagen, Inc. | Method and system for microbiome-derived diagnostics and therapeutics for mental health associated conditions |
| US10246753B2 (en) | 2015-04-13 | 2019-04-02 | uBiome, Inc. | Method and system for characterizing mouth-associated conditions |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4297276A (en) * | 1979-03-23 | 1981-10-27 | Hoffman-La Roche Inc. | Thymosin beta 3 and beta 4 |
| CA2156735A1 (en) * | 1993-02-22 | 1994-09-01 | Ulrich-Christoph Von Arnim | Pharmaceutical compositions for the treatment of inflammatory or immunological diseases and a method for the treatment of said diseases |
| US5578570A (en) * | 1993-10-07 | 1996-11-26 | The George Washington University Medical Center | Method of treating septic shock using thymosin β4 |
| GB9806632D0 (en) | 1998-03-28 | 1998-05-27 | Stevenson Robert | Peptide factor |
| PT1100529E (pt) * | 1998-07-30 | 2005-10-31 | Us Gov Health & Human Serv | A timosina beta 4 promove a preparacao de feridas |
| AU4461300A (en) * | 1999-04-14 | 2000-11-14 | Southco, Inc. | Crescent hinge |
| AU2002336408B2 (en) * | 2001-08-29 | 2006-12-21 | Regenerx Biopharmaceuticals, Inc. | Methods of healing or preventing inflammation, damage and other changes that occur prior to, during or immediately after a myocardial event with thymosin beta 4, analogues, isoforms and other derivatives |
| KR102632066B1 (ko) | 2015-07-30 | 2024-02-02 | 가부시키가이샤 한도오따이 에네루기 켄큐쇼 | 발광 장치의 제작 방법, 발광 장치, 모듈, 및 전자 기기 |
-
2003
- 2003-02-06 EP EP10185311A patent/EP2266595A3/en not_active Withdrawn
- 2003-02-06 EP EP03808930A patent/EP1497322A4/en not_active Withdrawn
- 2003-02-06 WO PCT/US2003/003455 patent/WO2004035008A2/en not_active Ceased
- 2003-02-06 US US10/503,555 patent/US20060089310A1/en not_active Abandoned
- 2003-02-06 AU AU2003296875A patent/AU2003296875B2/en not_active Ceased
- 2003-02-06 CA CA002475053A patent/CA2475053A1/en not_active Abandoned
- 2003-02-06 JP JP2004545186A patent/JP2006507270A/ja active Pending
-
2008
- 2008-04-09 US US12/100,065 patent/US20110144020A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006507270A5 (enExample) | ||
| Langoth et al. | Thiolated chitosans: design and in vivo evaluation of a mucoadhesive buccal peptide drug delivery system | |
| ES2565564T3 (es) | Una composición que comprende un antibiótico y un dispersante | |
| JP5969457B2 (ja) | 化合物およびそれらの使用 | |
| DK1739178T3 (da) | Levering af trekløverpeptider | |
| US20030171281A1 (en) | Antimicrobial cationic peptides and formulations thereof | |
| EP1718325B1 (en) | Treatment of bacterial infections | |
| AU2003296875A1 (en) | Treatment of infections and other disorders | |
| CA2513567A1 (en) | Cop 1 for treatment of inflammatory bowel diseases | |
| EP1421108A2 (en) | Antimicrobial and anti-inflammatory peptides | |
| JP6157514B2 (ja) | 抗菌性ペプチド | |
| US20040152624A1 (en) | Oral lactoferrin in the treatment of sepsis | |
| JP2018531880A5 (enExample) | ||
| JP2009500045A5 (enExample) | ||
| JP2004534084A5 (enExample) | ||
| JP4554150B2 (ja) | 薬剤耐性菌による感染症治療剤 | |
| JP6018614B2 (ja) | アンギオテンシンi転換酵素抑制と血圧低下に用いる短鎖活性ペプチド | |
| CN101247721B (zh) | 包括酪蛋白衍生肽的药物组合物及其使用方法 | |
| CN101342187B (zh) | 一种治疗痢疾的药物组合物 | |
| CN101415725B (zh) | 具有生物活性的肽化合物、其制备及其应用 | |
| CN103384523B (zh) | 硝呋太尔在治疗由梭菌属物种所引起的感染中的用途 | |
| ITMI20091122A1 (it) | Formulazioni farmaceutiche per uso intravaginale nella prevenzione e terapia delle vulvo vaginiti e nel ripristino della fisiologia vaginale | |
| JP2009502810A5 (enExample) | ||
| US20220133699A1 (en) | Antibacterial Compositions | |
| CN1299698C (zh) | 圆口纲动物唾液腺分泌物在制药中的应用 |